InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
Annovis Bio (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap, as the company advances ongoing Phase 3 and extension studies in Alzheimer’s disease and Parkinson’s disease. The company said the article provides historical and scientific context for buntanetap’s progression, with current trials showing approximately 70% enrollment in early Alzheimer’s and 20%…